Increased expression of Netrin-4 is associated with allodynia in a trigeminal neuropathic pain model rats by infraorbital nerve injury

Yuka Honjo¹,², Yuki Fujita¹,³, Hitoshi Niwa², Toshihide Yamashita¹,³,⁴,⁵ *

¹ Department of Molecular Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ² Department of Dental Anesthesiology, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan, ³ Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan, ⁴ Department of Molecular Neuroscience, Osaka University, Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan, ⁵ Department of Neuro-Medical Science, Graduate School of Medicine, Osaka University, Osaka, Japan

* yamashita@molneu.med.osaka-u.ac.jp

Abstract

Neuropathic pain refers to pain caused by lesions or diseases of the somatosensory nervous system that is characteristically different from nociceptive pain. Moreover, neuropathic pain occurs in the maxillofacial region due to various factors and is treated using tricyclic antidepressants and nerve block therapy; however, some cases do not fully recover. Netrin is a secreted protein crucially involved in neural circuit formation during development, including cell migration, cell death, neurite formation, and synapse formation. Recent studies show Netrin-4 expressed in the dorsal horn of the spinal cord is associated with chronic pain. Here we found involvement of Netrin-4 in neuropathic pain in the maxillofacial region. Netrin-4, along with one of its receptors, Unc5B, are expressed in the caudal subnucleus of the trigeminal spinal tract nucleus. Inhibition of its binding by anti-Netrin-4 antibodies not only shows a behavioral analgesic effect but also neuronal activity suppression. There was increased Netrin-4 expression at 14 days after infraorbital nerve injury. Our findings suggest that Netrin-4 induced by peripheral nerve injury causes neuropathic pain via Unc5B.

Introduction

Neuropathic pain is defined as “pain caused by a lesion or disease of the somatosensory system” by the International Association for the Study of Pain [1] and is characteristically different from nociceptive pain. It involves spontaneous sensations (persistent or intermittent) and stimulation-induced pain (allodynia and hyperalgesia) in areas coinciding with the impaired innervation area, as well as various sensations induced by nerve damage. Moreover, there is a characteristic of converging abnormalities [2]. It might also involve the trigeminal nerve region as a result of various factors, including surgery-induced trauma, tumors, neurodegenerative diseases, etc. Specifically, during dental treatments, nerves are inevitably mechanically cut during teeth extraction; moreover, there could be accidental damage to the lingual nerve...
and inferior alveolar nerve during oral surgery. Consequently, there is a high possibility of neuropathic pain caused by nerve damage [3]. Its pharmacological treatments include tricyclic antidepressants, selective norepinephrine and serotonin reuptake inhibitors, opioid agonists, and nerve block treatments. However, there are some cases of insufficient analgesic effect or where treatment cannot be used due to age or side effects [4]. Therefore, there is a need to establish an effective treatment by elucidating a novel molecular mechanism.

Netrin, which is a laminin-related extracellular protein, was originally identified as an attractant molecule for axon guidance in the embryonic spinal cord [5, 6]. In mammals, there are four secreted types (Netrin-1, -3, -4, and -5) and two glycosylphosphatidylinositol-anchored types (Netrin-G1 and -G2) [6–8]. Secreted Netrins bind to DCC (deleted in colorectal cancer), Neogenin, and Unc5 (A–D) while Netrin-Gs bind to different proteins [9]. Previous studies have demonstrated the important roles of Netrin in cell migration, survival, axon branching, and synaptogenesis during neural development [10–13]. The role of Netrin during adulthood has remained unclear; however, there have been recent reports regarding its role.

Netrin-4 is very homologous to the laminin β1 chain. In adults, Netrin-4 is expressed in the lung, kidney, blood vessel, and most brain parts, including the upper trigeminal spinal tract nucleus [14]. Further, Netrin-4 binds to Unc5B in the spinal cord [13, 15]. We previously reported that Netrin-4 delivered by dorsal horn interneurons was involved in inflammatory and neuropathic pain and that inhibition of Netrin-4 binding to Unc5B suppressed post-nerve-injury neuropathic pain [16].

This study aimed to investigate the role of Netrin-4 in orofacial neuropathic pain. Specifically, we aimed to examine Netrin-4 and Unc5B expression in the trigeminal subnucleus caudalis (Vc) of adult rats after infraorbital nerve injury, as well as Netrin-4 effects on mechanical sensitivity using anti-Netrin-4 antibody administration in a chronic pain model.

Materials and methods

Animals

6–9-wk-old male Sprague-Dawley rats (190–300 g; Japan SLC) were used in this study. All experiments were accordance with the Osaka University Medical School Guide for the Care and Use of Laboratory Animals and were approved by Institute Committee of Osaka University (Permit Number: 28–058).

Models for orofacial neuropathic pain

Chronic constriction injury to rat’s infraorbital nerve (CCI-ION) was performed with some changes as has been previously described [17]. Rats were put under isoflurane anesthesia. A small incision was made at the edge of the left whisker pad, and left ION was exposed. Two nylon sutures (6–0 thread) were placed 2mm apart around the ION, and the wound was sutured after ligation of the IO. These ligations reduced the diameter of the nerve, but did not occlude it completely (CCI: ipsilateral side). And contralateral ION was exposed but did not undergo nerve ligation for sham injury (Sham: contralateral side). Hereinafter it is described as ‘CCI--Sham injury’. We used this model for all subsequent experiments, and the total number of rats which were analyzed in this study were 86 (make animal models; n = 23, administration of antibody; n = 27, immunohistochemical staining; n = 20, quantitative PCR; n = 16).

Behavioral testing

The mechanical sensitivity of animals was assessed by using the von Frey filament test, as previously described [18]. Rats were placed on an acrylic box (30×30×30 cm) and habituated for
5–10 min before any stimulation. Then mechanical stimulations (4, 8, 15 and 26 g) were applied to center of the whisker pad using von Fry filaments (Semmes-Weinstein Von Frey esthesiometer, Muromachi Kikai Co.). The head-withdrawal threshold of the mechanical stimulation on the whisker pad skin was defined as minimum pressure needs to evoke at least three reactions by five stimuli (positive reaction; withdrawal of the head, or an attack or escape). The cutoff to prevent tissue damage was determined as 26 g. Before CCI-sham injury, stimulation with 26 g filament did not induce any nociceptive reaction. The stimuli were applied before injury and 7, 14, 21 days after injury.

**Intracisternal administration of drugs**

At 14 days after CCI-Sham injury, rats were tested their behavior before administration and put under isoflurane anesthesia. Anesthesia rats were placed in a head holder. A skin incision was made from the back of calvarium to top of cervical spine. The atlanto-occipital membrane was dissected under a surgical microscope, and a micro syringe with a 29-gauge needle inserted into cisterna magna. A mouse anti-Netrin-4 antibody (AF1132, R&D Systems) or Normal Goat IgG (144–09531, Wako) was diluted to 30 μg with 50 μl saline and infusions of drugs were performed slowly. The skin and muscle wound were sutured rapidly.

**Immunohistochemistry**

Immunohistochemistry was performed as described previously (Hayano et al., 2016). 30 minutes after the behavior test, rats were deeply anesthetized and then transcardially perfused with 100ml PBS, followed by 200ml of ice-cold 4% paraformaldehyde (PFA) in a 0.1M phosphate buffer. Vc and upper cervical cord (C1-C2) were dissected and post-fixed in 4% PFA for 24 hours at 4°C. Tissues were transferred and stored in 30% sucrose in PBS 48 hours at 4°C. 30μm coronal sections were cut on a cryostat. Sections washed three times and incubated in blocking solution (5% BSA and 0.3% Triton X-100 in PBS) for 1 hour at room temperature. For double-labelling immunofluorescence histochemistry, sections were incubated for 24 or 48 h at 4°C with antibodies against Netrin-4 (1:50; HPA049832; ATLAS), Unc5B (1:200; HPA01141, ATLAS), NeuN (1:1000; MAB377, Millipore), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:200; #4370, CST), Iba1(1:200; ab5076, abcam), GFAP (1:200; G-A-5, Sigma-Aldrich). The sections were washed 3 times and incubated for 2 h at room temperature or overnight at 4°C with secondary antibodies (Alexa Fluor 488/568/594; 1:500; Thermo Fisher Scientific, Inc.). The sections were washed 3 times, slide-mounted, and cover-slipped in mounting medium with the nuclear stain 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories).

The number of pERK positive neurons in the all area of Vc and the laminae II of C1 was counted. The mean number of pERK-immunoreactive (pERK-IR) neurons was calculated from 6 tissue sections (Positions: -2160, -1440, -720, 0, +720 and +1440 μm from the obex).

**Quantitative PCR**

Total RNA was extracted from the Vc-C1 which was collected by Laser Microdissection technique (LMD7000, Leica) with TRizol reagent (15596018, Invitrogen). After cDNA synthesis (High Capacity cDNA RT Kit, Applied Biosystems), gene expression was quantified with a TaqMan Gene Expression Assay (Applied Biosystems). The following Taqman Assays were used: *Netrin-4* (Rn01760394_m1); *Unc5B* (Rn00573551_m1). Cycle threshold (Ct) values were calculated using the ΔΔCt method. All ΔCt values were normalized to rat glyceraldehyde-3-phosphate dehydrogenase (Rn99999916_s1)
Experimental design and statistical analysis

Statistical analysis was performed using the Mann-Whitney test for comparisons between two groups. For comparisons among multiple groups, the two-way Repeated-Measure ANOVA with the Bonferroni post-hoc test and 3-way ANOVA with the Tukey post-hoc tests or the Dunnett post-hoc tests were used. Differences with $P < 0.05$ were considered statistically significant. Statistical analyses were performed using Prism software (GraphPad software Inc.). All data are presented as the mean ± standard error of the mean.

Results

Development of hyperalgesia after CCI-Sham injury

The CCI-ION rat has been studied as a model of orofacial neuropathic pain [17, 19, 20]. To assess the pain-related behavior of the orofacial neuropathic pain rat model, we measured their head-withdrawal threshold to the whisker pad skin using the von Frey filament test. There was a significant decrease in the head-withdrawal threshold for mechanical stimulation of the ipsilateral side at 14 and 21 days after injury compared with the pre-injury day (Fig 1). There was no significant change in the contralateral side on any day.

Netrin-4 antibody attenuates pain-related behavior in a trigeminal neuropathic pain rat model

We directly administered anti-Netrin-4 antibody to the cisterna magna to examine whether anti-Netrin-4 antibody, which has an analgesic effect on neuropathic pain caused by sciatic injury, could attenuate pain-related behavior in the orofacial neuropathic pain rat model.
nerve injury [16], exerted an analgesic effect on neuropathic pain caused by infraorbital nerve injury.

First, Evans Blue was administered to confirm whether the antibody added from the cisterna magna reached the target Vc-C1 region (Fig 2A). Second, a fluorescent-labeled anti-Netrin-4 antibody was administered from the cisterna magna and analyzed to confirm whether it would bind to neuronal cells in the Vc (Lightning-Link Rapid Conjugation System DyLight488, Innova Biosciences), which was confirmed (Fig 2B and 2C).

After confirming that the antibody reached the target region after administration through direct puncture of the cisterna magna, we assessed changes in the head-withdrawal threshold after antibody administration. The anti-Netrin-4 or Control antibodies were administered at 14 days after CCI-Sham injury. Compared with the Control antibody group, the anti-Netrin-4 antibody group showed a significant increase in the head-withdrawal threshold of the ipsilateral side after one day of administration (at 15 days after CCI-Sham injury) (Fig 2D).

Suppression of the neuronal activation by anti-Netrin-4 antibody in the Vc
A previous study [16] reported that neurons were activated by Netrin-4 administration to the spinal cord. Therefore, we performed immunohistochemistry to determine the effect of anti-Netrin-4 antibody on neuronal activation in the Vc.

After the 14 treatment days where the head-withdrawal threshold was significantly altered by the CCI-Sham injury, there was the expression of anti-pERK antibody-positive cells on both the ipsilateral and contralateral sides (Fig 3A and 3B). There was a significant increase in the number of cells positive for both the anti-pERK and anti-NeuN antibodies on the ipsilateral side. However, we could not observe the pERK signals in Iba-1-positive cells (Fig 3C) or GFAP-positive cells (Fig 3D). Further, upon anti-Netrin-4 antibody administration, there was a significant decrease in the number of pERK-positive neurons on the ipsilateral side compared with the pre-administration values and those in the control antibody administration group (Fig 3E and 3F).

Post-CCI increased Netrin-4 expression in the Vc
Previous studies have reported Netrin-4 and Unc5B expression in a healthy adult human brain; specifically, Netrin-4 expression in the trigeminal spinal subnucleus interpolaris (Vi) [14]. Consequently, we hypothesized that there was Netin-4 and Unc5B expression in the Vc. Immunohistochemical examination revealed anti-Netrin-4 and anti-Unc5B antibody-positive cells in the Vc. (Fig 4A–4F). Moreover, there was neuronal expression of Netrin-4 and Unc5B in the Vc (Fig 4D and 4F). Furthermore, to examine whether there was an association of changes in the head-withdrawal threshold with those in Netrin-4 and Unc5B expression in the Vc, we performed quantitative mRNA analysis by real-time PCR. Compared with pre-injury levels, there was a significant increase in the Netrin-4, but not Unc5b, levels from 7 to 21 days on both sides in the Vc after CCI (Fig 4G and 4H). We examined expression of Netrin-4 and Unc5B at 0 and 14 days (Fig 5A, 5B, 5E and 5F), and after anti-Netrin-4 antibody or control antibody treatment (Fig 5C, 5D, 5G and 5H). We did not observe the difference of the expression of Netrin-4 between ipsilateral and contralateral side in each group examined (Fig 5A–5H).

Discussion
The model of orofacial neuropathic pain established through infraorbital nerve injury
In this study, we used a rat model established through CCI-ION to analyze the effect of the anti-Netrin-4 antibody on trigeminal neuropathic pain. This model has been used in
Fig 2. Effects of anti-Netrin-4 antibody administration on pain behavior in trigeminal neuropathic pain model rats. (A) Confirmation of administration area by Evans Blue. (B and C) Penetration of anti-Netrin-4 antibody (Antibody) into the Vc. Double immunofluorescence staining for the fluorescence dye-conjugated Netrin-4 antibody (DyLight 488; green) and NeuN (red). The fluorescence of antibody was observed on neurons (arrowhead) in Vc. (C) is high magnification image corresponding to the square area in (B). Bars: (B) 100 μm, (C) 20 μm. (D) Head-withdrawal threshold after administration control IgG or anti-Netrin-4 antibody to CCI-ION or Sham injury (n = 5). The data are presented as the mean ± SEM. *, P<0.05; Tukey test.

https://doi.org/10.1371/journal.pone.0251013.g002
Netrin-4 is associated with allodynia in a trigeminal neuropathic pain

A

ipsi
contra

no antibody
(14day)

pERK

F

ipsi
contra

anti Netrin-4 antibody

Control antibody

pERK

B

pERK
NeuN

DAPI
Merge

C

pERK
lsat

Merge

D

pERK
GFAP

Merge

E

pERK-IR neuron cells/section

no Control antibody Netrin-4 antibody

*
numerous studies [17, 19, 20]; moreover, it has been reported that chronic injury caused by periphera nerve ligation induces allodynia or hyperalgesia to chemical, mechanical, and thermal stimuli [17, 21, 22]. In the established CCI-Sham injury model, infraorbital nerve ligation (CCI-injury) and non-ligation (Sham injury) were performed in the same rat. Numerous studies have analyzed the head-withdrawal threshold between the infraorbital nerve injury group (CCI-ION) and the pseudo injury group (Sham). A study reported a slightly decreased threshold on the injured and healthy side of the Sham and CCI-ION group, which recovered on 14 days after injury [19]. We observed recovery on the contralateral side and a significant decrease in the ipsilateral side at 14 days after injury. Therefore, to minimize the number of rats used in the experiment, we employed this method where the CCI-Sham injury was performed in the same rat.

The decreased escape thresholds caused by CCI-ION is observed from the first post-ligation day and lasts for at least 21 days [19, 20]. We observed the down threshold until 21 days after CCI-Sham injury. The hyperalgesia incidence on 14 days after CCI-Sham injury in our study was 30.4%, which is consistent with a previous study that employed a separate CCI and sham group [23].

Our findings indicated that allodynia developed on the ipsilateral side at 14 days after CCI--Sham injury and persisted until 21 days. Subsequent assessments of these rat models revealed a decreased head-withdrawal threshold at 14 days after injury.

The mechanism of hyperalgesia and the role of Netrin-4

Ligation and inflammation could induce peripheral nerve injury. Inflammatory factors, including bradykinin and prostaglandin, decrease the threshold of Transient Receptor Potential Vanilloid 1 and increase Na+ channel excitability via individual receptors located on the peripheral side of the primary afferent nerve, which causes peripheral sensitization [24]. Subsequently, glutamate, Substance P, and brain-derived neurotrophic factor released from the central site of the primary afferent nerve bind to individual neuron receptors in the secondary afferent nerve. This is followed by MEK phosphorylation, which leads to ERK activation. This leads to the activation of the cAMP response element-binding protein in the neuron nucleus and expression of various genes, including c-Fos and Neurokinin 1 (NK-1) [25–27]. It has been reported that pERK triggers post-translational regulation of AMPA and NMDA receptor and contributes to central sensitization [28–30]. This sensitization is thought to lead to increased neuronal excitability, as well as allodynia and hyperalgesia occurrence. After spinal cord injury, there is temporary pERK expression at the surface of the spinal dorsal horn; subsequently, there is long-term pERK expression in microglia and astrocytes [31]. Direct pERK inhibition by a selective MEK inhibitor reduces formalin-induced pain behavior. Therefore, pERK is considered to be deeply involved in neuropathic development and maintenance [32, 33]. We observed a greater increase in pERK-positive neurons in the ipsilateral side than in the contralateral side at 14 days after CCI-Sham injury. This suggests that peripheral and central sensitization occurred at 14 days after injury and that neurons of the Vc contribute to hyperalgesia through pERK expression. However, the number of pERK-positive neurons in our study

![Fig 3. Suppression of neuronal activation by administration of anti-Netrin-4 antibody.](https://doi.org/10.1371/journal.pone.0251013.g003)
was much less than that of previous reports [20, 34]. This could be partly attributed to differences in the mechanical stimulus intensity and stimulation method applied to the model. However, even with sciatic nerve or spinal cord injury induced by a slight stimulus, increased pERK expression has still been reported [35, 36]. Moreover, pERK expression has been reported to peak at several minutes after the noxious stimulus and to decrease by half after 10 minutes [32]. These findings suggest that differences in the number of cells could be attributed to differences in the time until tissue collection after mechanical stimulation. Further, there could have been reduced expression compared to that immediately after mechanical stimulation. Therefore, if tissues had been collected sooner after mechanical stimulation, the number of pERK-positive neurons could have been confirmed to correspond to the observed pain behavior. Further, 30 minutes after mechanical stimulation, there was a small total number of pERK-positive neurons; nonetheless, it was significantly higher in the ipsilateral side than on the contralateral side. Moreover, sustained nerve cell activation may cause long-term neuropathic pain.

Contrastingly, upon spinal cord injury, SHP2 and NR2B, which are among the NMDA receptor subtypes, are activated when Netrin-4 secreted from interneurons in the lamina 2 of the dorsal horn binds to Unc5B [16]. Consequently, neurons are activated while neuropathic pain and inflammatory pain occurs. We observed that anti-Netrin-4 antibody administration through the cisterna magna increased the escape threshold by CCI-ION and reduced neuronal pERK expression in the Vc. However, Netrin-4 expression is increased also in the contralateral side at day 14. These findings suggest that Netrin-4 enhances hypersensitivity induced by damage to the infraorbital nerve, but that Netrin-4 is not sufficient to induce hypersensitivity. The molecular mechanism of the effect of Netrin-4 in the Vc might be explained by the previous observations that Netrin-4 binding to Unc5B leads to activation of SHP2 and the Ras-MAPK pathway [16, 37–43].

The expression of Netrin-4 and Unc5B in Vc

Netrin-4 occurrence ranges widely in adult healthy brains in rats. It is not only expressed in the cerebral cortex but also the trigeminal spinal tract (Sp5) and Vi [14]. Therefore, Netrin-4 expression in the Vc is expected. Further, Unc5B has been reported as among the Netrin receptors that bind Netrin-1 or Netrin-4 [6, 13, 44].

Immunohistochemical analysis revealed Netrin-4 and Unc5B expression in the Vc~C1 at 14 days after CCI-Sham injury which was the day of hyperalgesia development. Moreover, quantitative mRNA analysis of the Vc~C1 indicated significantly increased Netrin-4 at 14 days after CCI-Sham injury compared with before injury. This indicates that hyperalgesia is caused by increased netrin-4 secretion, which triggers neuronal activation. In our study, although the number of Netrin-4–positive cells in the Vc appear to be a few, it may reflect the sensitivity of the antibodies employed. As Netrin-4 is a secreted protein, it would be difficult to detect the low amount of the Netrin-4 protein by immunohistochemistry. It should also be noted that the mechanism of upregulation of Netrin-4 in the Vc region remains a question and should be explored in the future.
Fig 5. Expression of Netrin-4 and Unc5B receptor in Vc-C1. (A and B) Netrin-4 expression in Vc of ipsilateral and contralateral side at 0 and 14 days. (C and D) Netrin-4 expression in Vc of ipsilateral and contralateral side after anti-Netrin-4 antibody or Control antibody treatment. (E and F) Unc5B expression in Vc of ipsilateral and contralateral side at 0 and 14 days. (G and H) Unc5B expression in Vc of ipsilateral and contralateral side after anti-Netrin-4 antibody or Control antibody treatment. Bars: 100 μm.

https://doi.org/10.1371/journal.pone.0251013.g005
Contrastingly, there was no change in Unc5B mRNA expression in the Vc although it was increased in the spinal cord after nerve injury. This could be attributed to differences between the brain and spinal cord; however, it has been reported that Unc5B mRNA expression decreased and recovered after spinal cord injury [45]. Therefore, Unc5B may show different changes at other time points. Further, it is possible that there are changes in Unc5B protein levels at 14 days after CCI-Sham injury. Therefore, there is a need for further studies. Furthermore, Netrin-4 has been reported to bind to laminin-γ1[46, 47]. Therefore, there is a need to consider the involvement of receptors other than Unc5B.

Moreover, there was no significant difference in mRNA Netrin-4 and Unc5B expression in the Vc between the ipsilateral side and contralateral side despite these differences being observed in the spinal cord. This suggests that SHP2 and NR2B activation change at the ipsilateral side of the Vc similar to in the spinal cord [16]. There is a need for further analysis to elucidate the underlying mechanism.

The analgesic effects of anti-Netrin-4 antibody

We observed that the administration of the anti-Netrin-4 antibody through the cisterna magna increased the head-withdrawal threshold for mechanical stimulation and suppressed neuronal activation in the Vc. These findings suggest that the anti-Netrin-4 antibody presents an analgesic effect by inhibiting the binding of Netrin-4 to Unc5B.

In adult humans, Netrin-4 is present in the heart, kidney, and spleen; further, it is slightly expressed in the brain and spinal cord [7, 48]. The presence of Netrin-4 widely varies in adult healthy brains in rats [14]. There is no abnormality in nerve circuit formation, as well as reproduction and organ formation, in the developmental stage of Netrin-4 knockout rats [16]. The anti-Netrin-4 antibody used in our study has been shown to reduce neuropathic pain caused by infraorbital nerve injury. Moreover, it did not induce significant weight loss or death upon administration. These findings suggest that the anti-Netrin-4 antibody is relative safety in animals and could be applied to humans.

Our findings suggest the following: CCI-ION induced persistent trigeminal nerve excitation and increased Netrin-4 secretion. Subsequently, hyperalgesia was induced by increased Netrin-4 binding to Unc5B. Other than suppressing neuronal activity, anti-Netrin-4 antibody is effective for pain hypersensitivity due to neuropathic pain and could be used in humans in the future.

Author Contributions

Conceptualization: Yuka Honjo, Yuki Fujita, Toshihide Yamashita.
Data curation: Yuka Honjo, Yuki Fujita.
Formal analysis: Yuka Honjo, Yuki Fujita.
Investigation: Yuka Honjo, Yuki Fujita.
Methodology: Yuka Honjo, Yuki Fujita.
Supervision: Yuki Fujita, Hitoshi Niwa, Toshihide Yamashita.
Validation: Yuki Fujita.
Writing – original draft: Yuka Honjo.
Writing – review & editing: Yuki Fujita, Toshihide Yamashita.
References

1. Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain. 2011; 152(11):2204–5. https://doi.org/10.1016/j.pain.2011.06.017 PMID: 21764514

2. International Association for the Study of Pain. Diagnosis and classification of neuropathic pain. IASP Pain Clinical Updates. 2010; 28:1–6. https://doi.org/10.1016/j.pain.2010.11.027 PMID: 2118120

3. Chiba M, Higuchi K, Kondoh T, Echigo S (2008) Clinical picture of neuropathic trigeminal pain provoked by dental treatment. Journal of the Japanese Stomatological Society. 2008; 57(4):379–84. PMID: 200962023.

4. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology. 2010; 9(8):807–19. https://doi.org/10.1016/S1474-4422(10)70143-5 PMID: 20650402

5. Kennedy TE, Serafini T, de la Torre J, Tessier-Lavigne M. Netrins are diffusible chemotactic factors for commissural axons in the embryonic spinal cord. Cell. 1994; 78(3):425–35. https://doi.org/10.1016/0092-8674(94)90421-9 PMID: 8062383

6. Cirulli V, Yebra M. Netrins: beyond the brain. Nature reviews Molecular cell biology. 2007; 8(4):296. https://doi.org/10.1038/nrm2142 PMID: 17356579

7. Koch M, Murrell JR, Hunter DD, Olson PF, Jin W, Keene DR, et al. A Novel Member of the Netrin Family, β-Netrin, Shares Homology with the β Chain of LamininIdentification, Expression, and Functional Characterization. The Journal of cell biology. 2000; 151(2):221–34. https://doi.org/10.1083/jcb.151.2.221 PMID: 11038171

8. Nakashiba T, Ikeda T, Nishimura S, Tashiro K, Honjo T, Culotti JG, et al. Netrin-G1: a novel glycosyl phosphatidylinositol-linked mammalian netrin that is functionally divergent from classical netrins. Journal of Neuroscience. 2000; 20(17):6540–50. https://doi.org/10.1523/JNEUROSCI.20-17-06540.2000 PMID: 10964959

9. Sun KLW, Correia JP, Kennedy TE. Netrins: versatile extracellular cues with diverse functions. Development. 2011; 138(11):2153–69. https://doi.org/10.1242/dev.044529 PMID: 21558366

10. Schwarting GA, Raitcheva D, Bless EP, Ackerman SL, Tobet S. Netrin-1-mediated chemotraction regulates the migratory pathway of LHRH neurons. European Journal of Neuroscience. 2004; 19(1):11–20. https://doi.org/10.1111/j.1460-9568.2004.03094.x PMID: 14750959

11. Manitt C, Nikolakopoulou AM, Almario DR, Nguyen SA, Cohen-Cory S. Netrin participates in the development of retinotectal synaptic connectivity by modulating axon arborization and synapse formation in the developing brain. Journal of Neuroscience. 2009; 29(36):11065–77. https://doi.org/10.1523/JNEUROSCI.0947-09.2009 PMID: 19741113

12. Takemoto M, Hattori Y, Zhao H, Sato H, Tamada A, Sasaki S, et al. Laminar and areal expression of unc5d and its role in cortical cell survival. Cerebral cortex. 2011; 21(8):1925–34. https://doi.org/10.1093/cercor/bhq265 PMID: 21216843

13. Hayano Y, Sasaki K, Ohmura N, Takemoto M, Maeda Y, Yamashita T, et al. Netrin-4 regulates thalamocortical axon branching in an activity-dependent fashion. Proceedings of the National Academy of Sciences. 2014; 111(42):15226–31.

14. Zhang C, Meng F, Wang C, Guo H, Fan M, Liu S, et al. Identification of a novel alternative splicing form of human netrin-4 and analyzing the expression patterns in adult rat brain. Molecular brain research. 2004; 130(1–2):68–80. https://doi.org/10.1016/j.molbrainres.2004.07.009 PMID: 15519678

15. Manitt C, Thompson KM, Kennedy TE. Developmental shift in expression of netrin receptors in the rat spinal cord: Predominance of UNC-5 homologues in adulthood. Journal of Neuroscience research. 2004; 77(5):690–700. https://doi.org/10.1002/jnr.20199 PMID: 15352215

16. Hayano Y, Takasu K, Koyama Y, Yamada M, Ogawa K, Minami K, et al. Dorsal horn interneuron-derived Netrin-4 contributes to spinal sensitization in chronic pain via Unc5B. Journal of Experimental Medicine. 2016; 213(13):2949–66. https://doi.org/10.1084/jem.20160877 PMID: 27856613

17. Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat’s infraorbital nerve. Journal of Neuroscience. 1994; 14(5):2708–23. https://doi.org/10.1523/JNEUROSCI.14-05-02708.1994 PMID: 8182437

18. Toyama M, Kudo C, Mukai C, Inoue M, Oyama Y, Hanamoto H, et al. Trigeminal nervous system sensitization by infraorbital nerve injury enhances responses in a migraine model. Cephalalgia. 2017; 37(14):1317–28. https://doi.org/10.1177/0333102416678387 PMID: 27919018

19. Nakajima A, Tsuboi Y, Suzuki I, Honda K, Shinoda M, Kondo M, et al. PKCγ in Vc and C1/C2 is Involved in Trigeminal neuropathic Pain. Journal of dental research. 2011; 90(6):777–81. https://doi.org/10.1177/0022034511401406 PMID: 21393551
20. Suzuki I, Tsuboi Y, Shinoda M, Shibuta K, Honda K, Katagiri A, et al. Involvement of ERK phosphorylation of trigeminal spinal subnucleus caudalis neurons in thermal hypersensitivity in rats with infraorbital nerve injury. PLoS One. 2013; 8(2): https://doi.org/10.1371/journal.pone.0057278 PMID: 23451198

21. Clavelou P, Pajot J, Dallel R, Raboison P. Application of the formalin test to the study of orofacial pain in the rat. Neuroscience letters. 1989; 103(3):349–53. https://doi.org/10.1016/0304-3940(89)90125-0 PMID: 2812522

22. Imamura Y, Kawamoto H, Nakanishi O. Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats. Experimental brain research. 1997; 116(1):97–103. https://doi.org/10.1007/pk00005748 PMID: 9305818

23. Sanuki T, Sakuma Y, Kan Y, Ando T, Kotani J (2007) Formalin Stimulation to Rat Infraorbital Nerve CCI Mode1. Journal of Japanese Dental Society of Anesthesiology. 2007; 35(2):158–62. PMID: 2007197368.

24. Scholz J, Woolf CJ. Can we conquer pain? Nature neuroscience. 2002; 5(11):1062 –7. https://doi.org/10.1038/nn942 PMID: 12403987

25. Ji R-R, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiology of disease. 2001; 8(1):1–10. https://doi.org/10.1006/ nbdi.2000.0360 PMID: 11162235

26. Ji R-R, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends in neurosciences. 2003; 26(12):696–705. https://doi.org/10.1016/j.tins.2003.09.017 PMID: 14624855

27. Ji R-R, Gereau Iv RW, Malcangio M, Strichartz GR. MAP kinase and pain. Brain research reviews. 2009; 60(1):135–48. https://doi.org/10.1016/j.brainresrev.2008.12.011 PMID: 19150373

28. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. science. 2000; 288(5472):1765–8. https://doi.org/10.1126/science.288.5472.1765 PMID: 10846153

29. Slack SE, Pezet S, McMahon SB, Thompson SWN, Malcangio M. Brain-derived neurotrophic factor induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. European Journal of Neuroscience. 2004; 20(7):1769–78. https://doi.org/10.1111/j.1460-9568.2004.03656.x PMID: 15379998

30. Kohno T, Wang H, Amaya F, Brenner GJ, Cheng J-K, Ji R-R, et al. Bradykinin enhances ERK activation in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity. Journal of Neuroscience. 2008; 28(17):4533–40. https://doi.org/10.1523/ JNEUROSCI.5349-07.2008 PMID: 18434532

31. Zhuang Z-Y, Gerner P, Woolf CJ, Ji R-R. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain. 2005; 114(1–2):149–59. https://doi.org/10.1016/j.pain.2004.12.022 PMID: 15733640

32. Gao Y-J, Ji R-R. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? The open pain journal. 2009; 2:11. https://doi.org/10.2174/1876386300902010011 PMID: 19898681

33. Ji R-R, Baba H, Brenner GJ, Woolf CJ. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nature neuroscience. 1999; 2(12):1114–9. https://doi.org/10.1038/16040 PMID: 10570489

34. Shibuta K, Suzuki I, Shinoda M, Tsuboi Y, Honda K, Shimizu N, et al. Organization of hyperactive microglial cells in trigeminal spinal subnucleus caudalis and upper cervical spinal cord associated with orofacial neuropathic pain. Brain research. 2012; 1451:74–86. https://doi.org/10.1016/j.brainres.2012.02.023 PMID: 22459040

35. Wang H, Dai Y, Fukuoka T, Yamanaka H, Obata K, Tokunaga A, et al. Enhancement of stimulation-induced ERK activation in the dorsal spinal cord and gracile nucleus neurons in rats with peripheral nerve injury. European Journal of Neuroscience. 2004; 19(4):884–90. https://doi.org/10.1111/j.1460-9568.2004.03203.x PMID: 1509135

36. Gao YJ, Ji RR. Light touch induces ERK activation in superficial dorsal horn neurons after inflammation: involvement of spinal astrocytes and JNK signaling in touch-evoked central sensitization and mechanical allodynia. Journal of neurochemistry. 2010; 115(2):505–14. https://doi.org/10.1111/j.1471-4159.2010.06946.x PMID: 20722971

37. Tong J, Killen M, Steven R, Binns KL, Culotti J, Pawson T. Nettin stimulates tyrosine phosphorylation of the UNC-5 family of netrin receptors and induces Shp2 binding to the RCM cytodomain. J Biol Chem. 2001; 276(44):40917–25. Epub 2001/09/05. https://doi.org/10.1074/jbc.M103672200 PMID: 11533026.

38. Krapivinsky G, Krapivinsky L, Manasian Y, Ivanov A, Tyzio R, Pellegrino C, et al. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003; 40(4):775–84. Epub 2003/11/19. https://doi.org/10.1016/s0896-6273(03)00645-7 PMID: 14622581.
39. Kim MJ, Dunah AW, Wang YT, Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron. 2005; 46(5):745–60. Epub 2005/06/01. https://doi.org/10.1016/j.neuron.2005.04.031 PMID: 15924861.

40. Easton JB, Royer AR, Middlemas DS. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor. J Neurochem. 2006; 97(3):834–45. Epub 2006/04/01. https://doi.org/10.1111/j.1471-4159.2006.03789.x PMID: 16573649.

41. Round J, Stein E. Netrin signaling leading to directed growth cone steering. Curr Opin Neurobiol. 2007; 17(1):15–21. Epub 2007/01/27. https://doi.org/10.1016/j.conb.2007.01.003 PMID: 17254765.

42. Peng HY, Chen GD, Lai CY, Hsieh MC, Lin TB. Spinal SIRPα1-SHP2 interaction regulates spinal nerve ligation-induced neuropathic pain via PSD-95-dependent NR2B activation in rats. Pain. 2012; 153 (5):1042–53. Epub 2012/03/20. https://doi.org/10.1016/j.pain.2012.02.006 PMID: 22425446.

43. Abbasi M, Gupta V, Chitranshi N, You Y, Dheer Y, Mirzaei M, et al. Regulation of Brain-Derived Neurotrophic Factor and Growth Factor Signaling Pathways by Tyrosine Phosphatase Shp2 in the Retina: A Brief Review. Front Cell Neurosci. 2018; 12:125. Epub 2018/04/11. https://doi.org/10.3389/fncel.2018.00085 PMID: 29636665; PubMed Central PMCID: PMC5880906.

44. Lejmi E, Leconte L, Pédron-Mazoyer S, Ropert S, Raoul W, Lavallette S, et al. Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B. Proceedings of the National Academy of Sciences. 2008; 105(34):12491–6. https://doi.org/10.1073/pnas.0804008105 PMID: 18719102

45. Ahn KJ, Seo IA, Lee HK, Choi EJ, Seo EH, Lee HJ, et al. Down-regulation of UNC5 homologue expression after the spinal cord injury in the adult rat. Neuroscience letters. 2007; 419(1):43–8. https://doi.org/10.1016/j.neulet.2007.03.068 PMID: 17452076

46. Schneiders FI, Maertens B, Böse K, Li Y, Brunken WJ, Paulsson M, et al. Binding of netrin-4 to laminin short arms regulates basement membrane assembly. Journal of Biological Chemistry. 2007; 282 (33):23750–8. https://doi.org/10.1074/jbc.M703137200 PMID: 17588941

47. Reuten R, Patel TR, McDougall M, Rama N, Nikodemus D, Gibert B, et al. Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes. Nature communications. 2016; 7(1):1–17. https://doi.org/10.1038/ncomms13515 PMID: 27901020

48. Yin Y, Sanes JR, Miner JH. Identification and expression of mouse netrin-4. Mechanisms of development. 2000; 96(1):115–9. https://doi.org/10.1016/s0925-4773(00)00369-5 PMID: 10940631